Over the past decade, consumer electronics divisions at major tech firms have driven growth, with hits like Apple’s (AAPL) ...

Amazon ( ($AMZN) ) has been popular among investors this week. Here is a recap of the key news on this stock. Amazon is facing pressure to address ...

Amazon has a new ZeroOne team focused on “breakthrough” devices, and it’s led by Xbox cofounder and former Microsoft ...

J Allard, a former Microsoft executive and one of the minds behind the Zune, is leading a new team at Amazon, CNBC reports.Allard is officially the vice president of Amazon's ZeroOne, which, based ...

J Allard, a former Microsoft executive who helped create the Zune and the Courier, is now leading a team developing products at Amazon. Meta has entered into an agreement with the US Army to build ...

An internal OpenAI strategy document titled “ChatGPT: H1 2025 Strategy” describes the company’s aspiration to build an “AI ...

“It’s a sign of the times: Even The New York Times, long known for its staunch defense against illegal content scraping and its high-profile legal battle with OpenAl, has signaled that it’s open to an ...

Visit americanexpress.com to learn more. One of the best ways to maximize your Amazon purchases is with an Amazon credit card. If you're looking for the right rewards credit card, our top pick is ...

While a trip to Home Goods gives us a serotonin boost, nothing quite measures up to how productive, speedy and satisfying it is to pick up some of the best home products on Amazon. As the sworn-in ...

It also said that J&J has reached an agreement with one of the lawyers resisting a deal, Allen Smith, who along with another firm represents around 12,000 plaintiffs out of several tens of ...

Whether you're running around the city streets, picnicking in the park, squeezing in a workout under the sun, or lounging poolside at your hotel, make sure you’re ready to handle the summer’s ...

Once-daily oral IL-23 inhibitor icotrokinra (formerly JNJ-2113) – which J&J licensed from Protagonist Therapeutics in 2017 – hit both its main efficacy objectives in the ICONIC-LEAD trial ...